Fauci slams U.K.'s speedy review of Pfizer, BioNTech COVID-19 shot HHS enlists CVS to pilot administering Eli Lilly's antibody drug to high-risk patients Not just AstraZeneca: Hackers targeted 5 other COVID-19 drug developers, vaccine cold chain suppliers Sponsored: Predicting Landfall: A Dynamic Control Room for Taking on the COVID-19 Landscape FDA's Hahn defends pace of Pfizer COVID-19 vaccine review Your patient plans to travel despite COVID-19 risk? Here's the latest CDC guidance to share COVID-19 vaccines based on novel platforms show early promise in mice As COVID demand surges, BD blueprints $1.2B expansion to jack up prefilled syringe output by 50% Biopharma roundup: Dry ice, syringe makers respond to skyrocketing demand; Inovio inks manufacturing deal Banner Health posts $57.2M loss since start of 2020 but reports improving income from operations British health tech startup uMed raises cash for next-gen clinical trial work Featured Story | By Eric Sagonowsky The U.K.’s monumental approval for Pfizer and BioNTech’s COVID-19 vaccine turned heads worldwide, but one of the leading voices in the U.S. pandemic response argues the country’s regulators acted too quickly. read more |
| |
|---|
|
Top Stories By Paige Minemyer The Trump administration has purchased an additional 650,000 doses of Eli Lilly's antibody treatment for COVID-19 and enlisted CVS Health to pilot administering the therapy to patients in long-term care facilities and at home. read more By Angus Liu A few days ago, allegations were made against North Korean hackers for cyberattacking COVID-19 vaccine frontrunner AstraZeneca. Turns out, the British pharma wasn’t alone on Pyeongyang’s hunting list, which also included Johnson & Johnson, Novavax and three South Korean firms, according to The Wall Street Journal. read more Sponsored by: Syneos Health When it comes to COVID-19 commercialization, multiple disrupters are likely to impact an asset’s trajectory. Gain the real-time perspective needed to pivot fast in an ever changing environment. read more By Nick Paul Taylor FDA Commissioner Stephen Hahn, M.D., has defended the pace of the review of Pfizer’s COVID-19 vaccine on the grounds that a thorough assessment is needed to reassure a skeptical public. read more By Tina Reed Make no mistake: Federal officials recommend the American public stay home over the upcoming holidays in order to stem surges of the COVID-19 pandemic. But if an individual does plan to travel, here's how the CDC is advising public health officials. read more By Angus Liu Even as mRNA COVID-19 vaccines are advancing to market, researchers continue to look for alternative—and possibly better—options. Now, two teams from City of Hope and Canadian biotech Biovaxys Technology have reported positive animal data for their candidates that come from different technology platforms. read more By Fraiser Kansteiner Becton Dickinson masterminded the pre-fillable syringe, and decades later, it's a technology key to the global COVID-19 vaccine rollout. And with pandemic demand surging, BD is planning to shell out $1.2 billion to expand that very business. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner The pandemic has created dramatic surges in demand for certain medical supplies, and now that's occurring again for dry ice and syringes. Companies are scrambling to respond. Meanwhile, Inovio inked a new manufacturing deal for its INO-4800 vaccine. read more By Tina Reed Banner Health has continued to experience financial headwinds, posting a $57.2 million loss in the first nine months of the year compared to earnings of $393.4 million in the same period a year earlier. read more By Ben Adams London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers on both sides of the pond participate in more clinical studies. read more |
